VYOME HOLDINGS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
VYOME HOLDINGS, INC. (HIND) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $4500.00 per share for the 12-month period ending 2024-12-31, per its 10-Q filed 2025-11-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2025-11-14
- VYOME HOLDINGS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2020-03-31 was $1.87, a 17.98% decline year-over-year.
- VYOME HOLDINGS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2019-03-31 was $2.28, a 67.52% decline year-over-year.
- VYOME HOLDINGS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2018-03-31 was $7.02, a 25.64% decline year-over-year.
- VYOME HOLDINGS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2017-03-31 was $9.44.
- VYOME HOLDINGS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2020 was $0.79, a 93.49% decline from fiscal 2019.
- VYOME HOLDINGS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2019 was $12.13, a 153.77% increase from fiscal 2018.
- VYOME HOLDINGS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2018 was $4.78, a 50.31% decline from fiscal 2017.
- VYOME HOLDINGS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2017 was $9.62, a 63.61% increase from fiscal 2016.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2024-12-31 | $4500.00 10-Q · filed 2025-11-14 | |||
| 2020-12-31 | $0.79 10-K · filed 2021-03-12 | |||
| 2020-09-30 | $0.79 10-Q · filed 2020-11-06 | |||
| 2020-06-30 | $0.80 10-Q · filed 2020-07-30 | |||
| 2020-03-31 | $1.87 10-Q · filed 2020-06-19 | |||
| 2019-12-31 | $12.13 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $17.16 10-Q · filed 2019-11-08 | |||
| 2019-06-30 | $2.15 10-Q · filed 2019-07-24 | |||
| 2019-03-31 | $2.28 10-Q · filed 2019-05-10 | |||
| 2018-12-31 | $4.78 10-K · filed 2019-02-22 | |||
| 2018-09-30 | $4.92 10-Q · filed 2018-11-02 | |||
| 2018-06-30 | $4.96 10-Q · filed 2018-08-02 | |||
| 2018-03-31 | $7.02 10-Q · filed 2018-05-10 | |||
| 2017-12-31 | $9.62 10-K · filed 2018-03-05 | |||
| 2017-09-30 | $9.68 10-Q · filed 2017-11-03 | |||
| 2017-06-30 | $10.02 10-Q · filed 2017-08-02 | |||
| 2017-03-31 | $9.44 10-Q · filed 2017-05-10 | |||
| 2016-12-31 | $5.88 10-K · filed 2017-02-23 | |||
| 2016-09-30 | $1.85 10-Q · filed 2016-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |